The U.S. Food and Drug Administration (FDA) will hold a public meeting on March 27, 2026, to explore critical scientific and regulatory questions surrounding dietary supplement ingredients. Organized by the agency’s Human Foods Program, the meeting will take place at the Wiley Auditorium in College Park, Maryland, and is listed under Docket No. FDA-2026-N-2047. 

This meeting reflects FDA’s increasing focus on emerging ingredient technologies and the evolving interpretation of what qualifies as a dietary supplement ingredient under the Dietary Supplement Health and Education Act (DSHEA).

Key Topics and Sessions

The agenda features four main sessions addressing foundational and forward-looking issues:

1. Defining “Dietary Substance” Under DSHEA
The opening session will examine the statutory phrase “dietary substance for use by man to supplement the diet by increasing the total dietary intake.” Experts will discuss how newer ingredient categories fit within this definition and whether current interpretations remain adequate for today’s market. 

2. New Production Technologies
A major focus will be on modern manufacturing approaches such as precision fermentation, cell culture, recombinant production, and chemical synthesis. The panel will explore how these technologies affect the regulatory status and safety assessment of ingredients that may be chemically identical—or similar—to traditional substances. 

3. Identity of Complex Ingredient Types
The third session will address challenges in defining the identity of ingredients such as proteins, enzymes, and microorganisms. These categories are not explicitly listed in the statutory definition of dietary supplements, raising questions about classification and regulatory pathways. 

4. Public Comment Session
The meeting will conclude with an open public comment period, allowing stakeholders—including industry, academia, and consumer groups—to provide input directly to FDA officials. 

Why This Meeting Matters

This FDA initiative signals growing regulatory attention on novel and bioengineered supplement ingredients, an area experiencing rapid innovation. Technologies like precision fermentation and synthetic biology are blurring the line between traditional dietary substances and engineered compounds, creating uncertainty around classification, safety evaluation, and compliance.

For industry stakeholders, the discussions could shape:

• Future guidance on new dietary ingredient (NDI) notifications
• Regulatory expectations for bioengineered or fermentation-derived substances
• Standards for ingredient identity and characterization
• The broader interpretation of DSHEA in the context of modern science

EZFDA Takeaway

This meeting represents a pivotal moment for the dietary supplement sector. As innovation accelerates, FDA appears to be reassessing how existing legal frameworks apply to next-generation ingredients. Companies developing or using novel production methods should closely monitor outcomes, as they may influence future regulatory requirements, enforcement priorities, and market access.

Stakeholders are encouraged to participate or submit comments to help shape FDA’s approach to defining and regulating dietary supplement ingredients in the years ahead.